Related Experiment Video
Updated: Jul 15, 2026
07:30
Single Cell Measurement of Dopamine Release with Simultaneous Voltage-clamp and Amperometry
Published on: November 21, 2012
Simple transporter trafficking model for amphetamine-induced dopamine efflux.
Prasanna K Thwar1, Bipasha Guptaroy, Minjia Zhang
1Department of Chemical Engineering, University of Michigan, Ann Arbor, Michigan 48109, USA.
Synapse (New York, N.Y.)
|April 7, 2007
Summary
Amphetamine causes dopamine efflux via transporter trafficking, leading to addiction. Our model explains this mechanism, linking transporter movement to dopamine release and drug effects.
Area of Science:
- Neuroscience
- Pharmacology
- Computational Biology
Background:
- Amphetamines are drugs of abuse with excitatory and addictive effects.
- These effects are linked to dopamine (DA) regulation in the brain.
- The precise molecular mechanisms of amphetamine-induced dopamine efflux remain unclear.
Purpose of the Study:
- To elucidate the molecular mechanisms of amphetamine-induced dopamine efflux.
- To investigate the role of monoamine transporter trafficking in amphetamine's effects.
- To develop a mathematical model explaining dopamine efflux dynamics.
Main Methods:
- Developed an ordinary differential equation model for amphetamine-induced DA efflux.
- Incorporated mechanistic details of DA transporter regulation.
- Used experimental data to validate the model and track transporter concentrations.
Main Results:
- The model accurately describes experimental data on DA efflux.
- Demonstrated that amphetamine-induced transporter trafficking is crucial for sustained DA efflux.
- The model explains the influence of amphetamine and DA concentrations on efflux.
Conclusions:
- Transporter trafficking is a necessary mechanism for amphetamine-induced dopamine efflux.
- The developed model provides insights into the temporal and concentration-dependent aspects of DA efflux.
- This work advances understanding of the neurobiological basis of amphetamine addiction.
More Related Videos
Related Concept Videos
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:19Drug Absorption Mechanism: Carrier-Mediated Membrane Transport
Certain large, lipid-insoluble drug molecules that resemble amino acids, peptides, or glucose, require specialized carrier proteins to facilitate their diffusion across cell membranes. This transport can occur through either facilitated diffusion, which does not require energy input, or active transport, which does require energy input.
Facilitated diffusion is a passive process that utilizes human Solute Carrier (SLC) transporters. These transporters bind to the drug, undergo structural...
Facilitated diffusion is a passive process that utilizes human Solute Carrier (SLC) transporters. These transporters bind to the drug, undergo structural...
01:06Carrier-Mediated Transport
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion, mediated...
A recent model describes pravastatin's hepatobiliary excretion, mediated...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...